Research Analysts Issue Forecasts for TERN FY2030 Earnings

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) – Equities researchers at HC Wainwright issued their FY2030 EPS estimates for shares of Terns Pharmaceuticals in a research report issued to clients and investors on Wednesday, March 25th. HC Wainwright analyst A. Maldonado anticipates that the company will earn ($1.60) per share for the year. HC Wainwright has a “Neutral” rating and a $53.00 price objective on the stock. The consensus estimate for Terns Pharmaceuticals’ current full-year earnings is ($1.19) per share.

Several other analysts have also recently commented on TERN. Oppenheimer raised their price target on Terns Pharmaceuticals from $28.00 to $58.00 and gave the company an “outperform” rating in a report on Tuesday, December 9th. Weiss Ratings restated a “sell (e+)” rating on shares of Terns Pharmaceuticals in a research report on Monday, December 29th. UBS Group upgraded Terns Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, December 4th. Wall Street Zen downgraded shares of Terns Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Finally, Citizens Jmp increased their target price on Terns Pharmaceuticals from $35.00 to $57.00 and gave the stock a “market outperform” rating in a research report on Thursday, December 11th. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $57.33.

Terns Pharmaceuticals Stock Up 5.7%

Shares of NASDAQ:TERN opened at $52.86 on Thursday. The company has a market cap of $5.48 billion, a price-to-earnings ratio of -51.32 and a beta of -0.31. Terns Pharmaceuticals has a fifty-two week low of $1.87 and a fifty-two week high of $52.98. The firm’s 50-day simple moving average is $40.63 and its 200-day simple moving average is $28.57.

Hedge Funds Weigh In On Terns Pharmaceuticals

Institutional investors have recently made changes to their positions in the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in Terns Pharmaceuticals during the 4th quarter valued at $25,000. GAMMA Investing LLC boosted its position in Terns Pharmaceuticals by 762.4% during the 4th quarter. GAMMA Investing LLC now owns 871 shares of the company’s stock valued at $35,000 after purchasing an additional 770 shares during the period. Engineers Gate Manager LP acquired a new position in shares of Terns Pharmaceuticals during the second quarter valued at $41,000. iA Global Asset Management Inc. acquired a new position in Terns Pharmaceuticals during the 4th quarter valued at about $43,000. Finally, Canada Pension Plan Investment Board acquired a new position in shares of Terns Pharmaceuticals during the second quarter worth approximately $46,000. 98.26% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Terns Pharmaceuticals

In other news, insider Emil Kuriakose sold 1,155 shares of the company’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $38.57, for a total value of $44,548.35. Following the completion of the transaction, the insider directly owned 50,365 shares in the company, valued at approximately $1,942,578.05. This represents a 2.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Amy L. Burroughs sold 71,339 shares of the business’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $38.10, for a total transaction of $2,718,015.90. Following the completion of the transaction, the chief executive officer owned 138,976 shares in the company, valued at $5,294,985.60. This represents a 33.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 170,409 shares of company stock worth $6,563,769. 1.50% of the stock is currently owned by insiders.

Key Stories Impacting Terns Pharmaceuticals

Here are the key news stories impacting Terns Pharmaceuticals this week:

• Positive Sentiment: Merck agreed to an all-cash acquisition at $53.00 per share, approved by both boards and structured as a tender offer with expected closing in Q2 2026 — the deal provides a clear near-term valuation floor and validates Terns’ lead asset, TERN-701, as strategically valuable to a large pharma buyer. Read More.
• Positive Sentiment: Major media and wire services emphasize the strategic fit (adding a CML allosteric BCR::ABL1 inhibitor) and Merck’s broader push to refill its oncology pipeline ahead of Keytruda’s patent cliff — reinforcing deal rationale for investors. Read More.
• Neutral Sentiment: HC Wainwright reaffirmed a “neutral” rating with a $53 price target (essentially aligned with the offer price), suggesting limited upside beyond the transaction price while the deal closes. Read More.
• Neutral Sentiment: Deal mechanics: transaction is a tender offer contingent on shareholder participation and customary closing conditions — market will watch vote/acceptance levels, regulatory review and timing rather than Terns’ standalone clinical milestones. Read More.
• Negative Sentiment: Multiple shareholder-law firms have launched investigations into whether Terns’ board obtained a fair price (Monteverde, Ademi, Halper Sadeh), which could lead to litigation, delay or pressure on deal terms — a risk for timing and transaction certainty. Read More. Read More. Read More.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.